When Local CAR-T Options are Limited, There May be Other Paths, in China
We help you access leading hematology and CAR-T centers in China.
Confidential case review • No obligation to travel
You may be exploring other options because:
I can not get it locally
I've exhausted standard treatments
My cancer has relapsed
I'm looking for superior CAR-T option
A Comparison
How China Compares on CAR-T
Complete remission rates: ~40–67% reported for relapsed/refractory lymphoma, and 60–80% for relapsed/refractory B-cell leukemia comparable to global benchmarks for US products
Manufacturing speed. China now has one of the largest bases of CAR-T manufacturing anywhere, a 9-day manufacturing turnaround is a life-saving metrics as compared to 4-week Western waitlist
High patient volume. Leading centers run high case volumes for CAR-T and hematology, supporting experienced clinical teams at a lower cost
China’s massive production hubs and elite expertise offer affordable and faster manufacturing.
《Nature》2025: China Overtakes the US in Cancer Research Output
China CAR-T THERAPY
China is
One of the Most Active Nations in Next-Gen CAR-T Therapy
9 APPROVED:
5 CD 19, 3 BCMA, 1 CLAUDIN 18.2
SOURCE: https://www.fiercebiotech.com/research/china-approved-worlds-first-solid-tumor-car-t-therapy-when-will-us-follow
Source: https://www.youtube.com/watch?v=DCK8PiFspPI&t=74s
Source: https://www.nature.com/articles/d41586-025-01154-4
Active Next-Generation Research Pipeline
Leading centers are advancing dual-target and allogeneic therapies, positioning China at the forefront of global CAR-T innovation.
Shorter Manufacturing Turnaround
Leveraging high-volume production to deliver a faster manufacturing timeline compared to traditional global standards.
Lymphoma, Leukemia, Multiple Myeloma, Pediatric, and World's First Solid Cancer
China has approved 9 CAR-T therapies, howeveer there are ~470 ongoing trials in liver cancer, pancreatic cancer and other solid cancers and blood cancers.
Talk to Us About Your Case
#1 Most Trusted Cross-Border Medical Service in Asia, 3000 patients served 10 years.
WHATSAPP our 24/7 on-duty medical staff
Jasmine is currently online and
can reply within 1 minute.
Whatsapp is preferred way to reach out to us.
If you don't have Whatsapp, email: support@medeboundhealth.com
ChinaCureLink: A Path to Treatment
HOW IT WORKS
For the last 10 years, we have helped more than 3000 patients worldwide seeking advanced care in the US and in China
04
05
Medical Visa
Travel & Treatment
We assist with the complex medical visa process, ensuring all documentation is in order for your travel.
Travel to China for your treatment, with our team providing on-the-ground support throughout your journey.
01
Free Advisory Call
We begin with a complimentary case review to assess your eligibility for CAR-T therapy in China.
02
Match 3 Top Hospitals
We identify and match you with
Top 3* hematology hospitals in China specializing in CAR-T therapy.
03
Consult With Physician
You choose hospital/physician, We set up a video consultation with Car T physician to review your eligibiity.
Top 3 HOSPITAL: ranked by CHINA's AUTHORITY HoSPITAL RATING SYSTEM PER PATIENTS VOLUME, RESEaRch OUTPUT,CLINICAL EXCELLENCE and OUTCOME
High-Volume Hematology & CAR-T Center
One of China's largest hematology and cellular-therapy programs
- #1 in China — 1,662 HSCT cases in 2025
- #1 in China — Registered beds & transplant units
- #1 in China — Hematology revenue
- 3,000+ CAR-T clinical study cases
- 385+ scientific publications, 2018–2025
- 208+ presentations at ASH, EHA & EBMT
- 270+ senior physicians across 4 specialized hospitals
- 30+ countries represented among international patients
Why it matters: Exceptional treatment volume means extensive experience managing complex blood cancers, transplantation, CAR-T treatment and treatment-related complications.
What Does a Top 3 CAR-T Hospital in China Look Like?
Not all CAR-T centers are the same. We focus on a small group of China's leading hematology and cellular-therapy centers, selected for treatment volume, clinical experience, research capabilities, transplant infrastructure, and ability to manage complex international patients.
Academic CAR-T & Clinical Research Center
A leading Chinese academic center for advanced cellular therapies
- Major academic hematology and oncology center
- Extensive CAR-T clinical research portfolio
- Experience across multiple CAR-T targets and treatment strategies
- Multidisciplinary teams for relapsed and refractory blood cancers
- Integrated transplantation, cellular therapy, ICU and complication-management capabilities
- Active participation in peer-reviewed clinical research
- Experience evaluating complex patients after multiple prior therapies
- Dedicated infrastructure for international patients
Why it matters: For patients who have exhausted standard treatment pathways, access to a research-intensive center may provide opportunities to explore additional cellular-therapy strategies based on individual eligibility.
We Don't Match Patients by Hospital Ranking Alone.
The “best” CAR-T center depends on your diagnosis, previous treatments, disease status, CAR-T target, transplant history and clinical eligibility. Our team reviews your case and identifies appropriate leading centers before you decide whether traveling to China makes sense.
Confidential review • No obligation to travel
Why Choose Us:
Physician-Led, Cross-Border 10 Years 3000+ Cases Served
Medebound Health, our parent company headquartered in New York, brings 10 years of experience in cross-border second opinions and medical concierge services, primarily connecting international patients with advanced care in the U.S.
Building on that foundation, ChinaCureLink was established to help international families access advanced treatment options in China, including CAR-T therapy.
Our physician-founded and physician-led team includes a Harvard-trained physician, a former president of a New York medical college, and other distinguished academic medical leaders.
ChinaCureLink goes beyond medical coordination. Our team has deep relationship with China's medical network, cross-border healthcare expertise. We provide end-to-end support — from medical evaluation and hospital access to treatment coordination and on-the-ground assistance in China.
Dr. Sheena Liu, MD, PhD , an alumna of Columbia University College of Physician and Surgeon, Co-Founded Medebound HEALTH/ChinaCureLink with a Harvard Senior Physician(Dr. White) and another Columbia Doctor(Dr. Connolly) , in the City of New York.
“Medebound/ChinaCureLink provided expert guidance for our family’s successful China treatment. They are a professional, trusted gateway to advanced care.”
Timeline Summary
01. 4 weeks: Inquiry & Physician Consultation
02. 2 weeks: Hospital Matching & Review
03. 14 days: Treatment Duration in China
04. 100%: Complete Remission
9 years of relapsing multiple myeloma: Elena, a 64-year-old woman from Italy, entered a BCMA-CAR-T program in China after her disease became relapsed and refractory, meaning it had returned despite prior treatments and was no longer responding meaningfully to earlier drugs.
BCMA-targeted CAR-T therapy: Her own T-cells were collected, genetically modified to recognize BCMA (B-cell maturation antigen) on myeloma cells, multiplied in a laboratory, and returned as CAR-T cells designed to target those cancer cells.
September 16 to October 23, 2019: Elena arrived in China on September 16, 2019, underwent specialist review and trial assessment, and received her BCMA-CAR-T infusion on October 23, 2019 at a JCI-accredited Top 1 hematology hospital in the Beijing region.
The hospital’s 700th CAR-T trial patient: Elena was the 700th patient enrolled in the hospital’s CAR-T clinical trial program, following its 600th enrolment—a 7-year-old child with B-cell acute lymphoblastic leukemia—just 4 months earlier.
ChinaCureLink support for international families: affiliated with Medebound HEALTH, a New York-headquartered medical concierge company with 10+ years of experience and 3,000+ patients served worldwide.
READ MORE
50-70%
Cost Savings
Significant reductions in treatment costs compared to traditional Western markets, achieved through high-volume manufacturing and hospital-set pricing models.
Two questions matter most when comparing countries:
What will it cost, and does it work effectively.
Why Families Choose China CART
Published data and hospital-level experience point to a consistent answer.
70+%
Response Rate
High patient response rates across leading centers, with outcomes comparable to U.S. products based on published clinical data.
5,000+
Accumulative Procedure Volume
Leading centers perform over 1,000 CAR-T procedures annually, providing extensive clinical experience and high-volume clinical expertise.
Frequently Asked Questions
1. Who is eligible for CAR-T therapy in China?
Eligibility is determined by the treating hospital based on clinical criteria which may include:
Newly diagnosed high-risk large B-cell lymphoma patients; Relapsed/refractory large B-cell lymphoma (r/r LBCL) patients; Relapsed/refractory follicular lymphoma (r/r FL, grades 1-3a) patients.Newly diagnosed high-risk acute lymphoblastic leukemia (B-ALL) patients; Relapsed/refractory mantle cell lymphoma (r/r MCL) patients; Relapsed/refractory multiple myeloma (r/r MM) patients; Relapsed/refractory acute lymphoblastic leukemia (r/r B-ALL, adult and pediatric) patients.
Age: Priority is given to ages 18-65; patients aged 65-75 require additional assessment of physical fitness and comorbidities, and those over 75 are generally not recommended but the oldest patient ChinaCureLink received was 78 year old.
2. What is the typical cost structure?
ChinaCureLink facilitates transparent price negotiations with China's top 3 hematology centers. Final expenses are confirmed via a direct video consultation with the hospital, guaranteeing no hidden costs. We provide a full financial breakdown, with typical treatment ranges between $160K and $200K USD.
3. How long does the initial consultation take?
We offer a complimentary first conversation with our physician-led team. This typically takes 40mins to discuss your medical history and treatment options in detail. Contact us to schedule such a call.
4. What is the process for medical visas?
We manage the entire medical visa application process. Our team handles the coordination with the hospital to ensure your travel documents are in order before you travel to China.
5. Are the medical bills covered by my insurance?
Less likely. But please check with your insurance. Occasionally some international insurance may cover portion of the medical cost.
6. What is the typical timeline for treatment?
The timeline varies by patient. From initial inquiry to hospital review, it typically takes 1-2 weeks. The actual treatment process, including manufacturing and infusion, is usually completed in 3-4 weeks. Plan to stay in China for at least 6 weeks.